| DB ID | MyCo_2545 |
| Title | Evaluation of (1 → 3)-β-D-glucan assay for diagnosing paracoccidioidomycosis |
| Year | 2019 |
| PMID | 31532045 |
| Fungal Diseases involved | Paracoccidioidomycosis |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The authors confirm that the ethical policies of the journal have been adhered to and the appropriate ethical review committee approval from Escola Paulista de Medicina, Universidade Federal de Sao Paulo (CEP-UNIFESP 1769/10) was received. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | Here selected a total of 52 serum samples sequentially obtained from 29 patients with active PCM confirmed by the identification of fungal elements characteristics of Paracoccidioides spp. In tissue samples stained by methenamine silver and hematoxylin-eosin, in the presence of a positive immunodiffusion tests in serum 2. All patients were admitted at the Hospital São Paulo, UNIFESP, and were representative of acute (N=17) and chronic forms (N=12) of the disease. Serum samples were collected at baseline (N=29 patients) and, for 16 patients, additional serum levels were obtained after 3 months (M3) and 6 months (M6) of antifungal treatment. Data on clinical and laboratorial response to antifungal therapy was collected along a 6 month period of follow-up, including imaging of lung, evaluation of signs and symptoms as well as results of conventional mycology tests (direct microscopy, cultures, histopathology and detection of anti P. brasiliensis antibodies by immunodiffusion). |
| Cohort No. | 29 Patients |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Paracoccidiodomycosis (PCM) is an endemic mycosis caused by Paracoccidioides brasiliensis and Paracoccidioides lutzii with high prevalence in Latin American countries1. The laboratory diagnosis of PCM relies upon the detection of the pathogen in biological samples and results of specific serological tests 2. Currently, no commercial system is available for detecting antigens or specific anti- Paracoccidioides antibodies in biologic samples of patients under investigation of PCM. In clinical practice, in-house double immunodiffusion assays with locally produced specific antigens are used for diagnosing patients with PCM and monitoring their response to therapy. |
| Technique | Assay |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Fungitell® assay Kit (Associates of Cape Cod, Inc., East Falmouth, MA, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
